Contact UsInvestorsCareersMediaScienceContact Us
HomeProductsPrescription MedicinesNgenla

This page is intended as reference information for the general public.

Ngenla▼ (somatrogon)

What is Ngenla and what is it used for?

Ngenla contains the active substance somatrogon, a modified form of human growth hormone. Natural human growth hormone is needed for bones and muscles to grow and helps fat and muscle tissue to develop in the right amounts.

Somatrogon is a long-acting, once-weekly human growth hormone molecule created using recombinant DNA technology – it is made by an organism that has received a gene (DNA), which makes it able to produce somatrogon.

Ngenla is used to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone and are not growing at a normal rate.

Ngenla is given as a once-weekly subcutaneous (under the skin) injection using a pre-filled pen. Patients and carers must refer to the instructions for use before using the medicine. The instructions are provided with the device.

Reference Information

The National Institute for Health and Care Excellence (NICE) provides national guidance and advice to improve health and social care. One of the ways they do this is by producing evidence-based guidance. See NICE guidance on Ngenla.

The Scottish Medicines Consortium (SMC) is the national source of advice on the clinical and cost-effectiveness of all medicines for NHS Scotland. Their aim is to ensure people in Scotland have timely access to medicines that provide most benefit based on best available evidence. See SMC guidance on Ngenla.

Medicines in Northern Ireland fall under the remit of the European Medicines Agency (EMA) whilst medicines in Great Britain (England, Scotland and Wales) fall under the remit of the Medicines and Healthcare products Regulatory Agency (MHRA) following the UK leaving the European Union. These agencies are responsible for the scientific evaluation, supervision and safety monitoring of medicines developed by pharmaceutical companies.

If you would like to see the Summary of Product Characteristics (SPC) or Patient Information Leaflet (PIL) for Ngenla please follow these links:

Great Britain

Ngenla (somatrogon)

Northern Ireland

Ngenla (somatrogon)

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information.

If you get any side effects when taking this or any other medicine, talk to your doctor or other relevant health professional e.g. pharmacist, nurse. This includes any possible side effects not listed in the packaging leaflet. You can also report side effects directly via the Yellow Card Scheme at or search the Google Play or Apple App Store for MHRA Yellow Card. By reporting side effects, you can help provide more information on the safety of this medicine.

Pfizer is unable to provide advice on personal medical matters. Please consult your doctor or other relevant health professional for specific, health-related advice and support.

PP-NGE-GBR-0336 / March 2023
Science Products Responsibility PartnershipsCareers Privacy Statement Terms of Use Contact UsSitemap Copyright © 2017-2024 Pfizer Limited. PP-UNP-GBR-8108 / January 2024. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427. This website is intended for the general public in the UK.